# Loss of oligodendrocyte transcription factor 2 protein expression in metabolically stressed oligodendrocytes

**Authors:** Hannes Kaddatz, Lukas Wenzel, Emil Pril, Sophia Meien, Victoria Harz, Luisa Burkert, Newshan Behrangi, Annelie Zimmermann, Linda Frintrop, Sandra Amor, Markus Kipp, Leo Heinig

PMC · DOI: 10.1007/s00401-026-03000-x · Acta Neuropathologica · 2026-03-24

## TL;DR

This study shows that stressed oligodendrocytes lose a key protein (OLIG2), which could be an early sign of myelin damage in diseases like multiple sclerosis.

## Contribution

The study identifies a post-transcriptional loss of OLIG2 in stressed oligodendrocytes as a novel early indicator of cell stress in demyelinating diseases.

## Key findings

- Stressed oligodendrocytes show reduced OLIG2 protein without changes in mRNA levels.
- OLIG2 loss occurs in both animal models and human MS lesions.
- Pharmacological intervention can reduce OLIG2 loss in stressed cells.

## Abstract

Oligodendrocytes are essential for myelin production, maintenance, and repair, and their dysfunction contributes to the pathogenesis of demyelinating diseases such as multiple sclerosis (MS). Here, we identify an early stress-associated oligodendrocyte state characterized by a rapid, post-transcriptional loss of the lineage-defining transcription factor Oligodendrocyte Transcription Factor 2 (OLIG2). Using the cuprizone model of toxic demyelination, we observed an early appearance of OLIG2low expressing oligodendrocytes, followed by the emergence of OLIG2-negative oligodendrocytes at later stages. This observation was particularly pronounced among cells expressing the integrated stress response marker Activating Transcription Factor 3 (ATF3). Transcriptomic analysis, quantitative PCR, and combined in situ hybridization–immunohistochemistry confirmed that these changes occurred without a corresponding reduction in Olig2 mRNA levels, indicating that OLIG2 protein loss is a stress-induced, post-transcriptional event not captured by RNA-level profiling. A similar phenotype was observed in a reversible metabolic stress paradigm (i.e., chronic starvation model) and in post-mortem MS lesions, where stressed oligodendrocytes showed reduced or absent OLIG2 protein expression. Pharmacological intervention with the sphingosine-1-phosphate receptor modulator siponimod during cuprizone intoxication attenuated OLIG2 protein loss, indicating that this stress-induced state is pharmacologically modifiable. These findings reveal a transient and potentially reversible phenotype in stressed oligodendrocytes that may precede overt cell loss or demyelination. Thus, OLIG2 protein loss may serve as an early indicator of oligodendrocyte stress and a possible therapeutic target for preserving myelin integrity in demyelinating disorders. These findings have additional methodological implications as stressed oligodendrocytes may evade detection using OLIG2-based lineage markers.

The online version contains supplementary material available at 10.1007/s00401-026-03000-x.

## Linked entities

- **Genes:** OLIG2 (oligodendrocyte transcription factor 2) [NCBI Gene 10215], ATF3 (activating transcription factor 3) [NCBI Gene 467]
- **Proteins:** OLIG2 (oligodendrocyte transcription factor 2)
- **Chemicals:** cuprizone (PubChem CID 9723), siponimod (PubChem CID 44599207)
- **Diseases:** multiple sclerosis (MONDO:0005301)

## Full-text entities

- **Genes:** Ddit3 (DNA-damage inducible transcript 3) [NCBI Gene 13198] {aka AltDDIT3, CHOP-10, CHOP10, chop, gadd153}, Olig2 (oligodendrocyte transcription factor 2) [NCBI Gene 50913] {aka Bhlhb1, Olg-2, Oligo2, RK17, bHLHe19}, Olig1 (oligodendrocyte transcription factor 1) [NCBI Gene 50914] {aka Bhlhb6, Olg-1, Oligo1, bHLHe21}, Eif2ak3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 13666] {aka Pek, Perk}, Car2 (carbonic anhydrase 2) [NCBI Gene 12349] {aka CAII, Ca2, Car-2, Ltw-5, Lvtw-5}, Atf3 (activating transcription factor 3) [NCBI Gene 11910] {aka LRG-21}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, PLP1 (proteolipid protein 1) [NCBI Gene 5354] {aka GPM6C, HLD1, MMPL, PLP, PLP/DM20, PMD}, Acd (adrenocortical dysplasia) [NCBI Gene 497652], Aif1 (allograft inflammatory factor 1) [NCBI Gene 11629] {aka AIF-1, D17H6S50E, G1, Iba1}, Plp1 (proteolipid protein (myelin) 1) [NCBI Gene 18823] {aka DM20, Plp, jimpy, jp, msd, rsh}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, S1pr5 (sphingosine-1-phosphate receptor 5) [NCBI Gene 94226] {aka Edg8, S1P5, lpB4}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, S1PR5 (sphingosine-1-phosphate receptor 5) [NCBI Gene 53637] {aka EDG8, Edg-8, S1P5, SPPR-1, SPPR-2}, Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], Sox10 (SRY (sex determining region Y)-box 10) [NCBI Gene 20665] {aka Dom, Sox21, gt}, RBFOX3 (RNA binding fox-1 homolog 3) [NCBI Gene 146713] {aka FOX-3, FOX3, HRNBP3, NEUN}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, ATF3 (activating transcription factor 3) [NCBI Gene 467], S1pr1 (sphingosine-1-phosphate receptor 1) [NCBI Gene 13609] {aka Edg1, Lpb1, S1p, S1p1}, Serpina3n (serine (or cysteine) peptidase inhibitor, clade A, member 3N) [NCBI Gene 20716] {aka Spi2-2, Spi2.2, Spi2/eb.4}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, ASPA (aspartoacylase) [NCBI Gene 443] {aka ACY2, ASP}, Aspa (aspartoacylase) [NCBI Gene 11484] {aka Acy-2, Acy2, nur7}, OLIG2 (oligodendrocyte transcription factor 2) [NCBI Gene 10215] {aka BHLHB1, OLIGO2, PRKCBP2, RACK17, bHLHe19}, Eif2ak2 (eukaryotic translation initiation factor 2-alpha kinase 2) [NCBI Gene 19106] {aka 2310047A08Rik, 4732414G15Rik, Pkr, Prkr, Tik}, Cspg4 (chondroitin sulfate proteoglycan 4) [NCBI Gene 121021] {aka 4732461B14Rik, AN2, Cspg4a, NG2}, S1PR1 (sphingosine-1-phosphate receptor 1) [NCBI Gene 1901] {aka CD363, CHEDG1, D1S3362, ECGF1, EDG-1, EDG1}, Hprt1 (hypoxanthine phosphoribosyltransferase 1) [NCBI Gene 15452] {aka HPGRT, Hprt}, Cnp (2',3'-cyclic nucleotide 3' phosphodiesterase) [NCBI Gene 12799] {aka CNPase, Cnp-1, Cnp1}
- **Diseases:** NAWM (MESH:D056784), infection (MESH:D007239), PMD (MESH:D020371), Lesion (MESH:D009059), malnutritional (MESH:D044342), cortical demyelination (MESH:D003711), death (MESH:D003643), primary progressive multiple sclerosis (MESH:D020528), toxicity (MESH:D064420), damage (MESH:D020263), mitochondrial dysfunction (MESH:D028361), neurological disease (MESH:D020271), respiratory distress (MESH:D012128), paralysis (MESH:D010243), MS (MESH:D009103), weight loss (MESH:D015431), hypoxia (MESH:D000860), stupor (MESH:D053608), neurological symptoms (MESH:D009461), energy failure (MESH:D051437), inflammatory (MESH:D007249), seizures (MESH:D012640), starvation (MESH:D013217), degeneration (MESH:D009410), CMCS (MESH:C535459)
- **Chemicals:** DAKO (-), Cuprizone (MESH:D003471), citrate (MESH:D019343), 3,3'-diaminobenzidine (MESH:D015100), acid (MESH:D000143), Carboxymethylcellulose sodium (MESH:D002266), DAB (MESH:C000469), 4',6-Diamidino-2-phenylindole (MESH:C007293), Paraformaldehyde (MESH:C003043), lipid (MESH:D008055), NADPH (MESH:D009249), biotin (MESH:D001710), EDTA (MESH:D004492), xylazine (MESH:D014991), reactive oxygen species (MESH:D017382), Paraffin (MESH:D010232), S1P (MESH:C060506), lipid peroxides (MESH:D008054), H2O2 (MESH:D006861), Siponimod (MESH:C578989), ATP (MESH:D000255), Tris (MESH:D014325), Fluorescein (MESH:D019793)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013231/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013231/full.md

---
Source: https://tomesphere.com/paper/PMC13013231